CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples

被引:31
作者
Cozzolino, Immacolata [1 ]
Varone, Valeria [2 ]
Picardi, Marco [3 ]
Baldi, Carlo [4 ]
Memoli, Domenico [4 ]
Ciancia, Giuseppe [2 ]
Selleri, Carmine [4 ]
De Rosa, Gaetano [2 ]
Vetrani, Antonio [1 ]
Zeppa, Pio [4 ]
机构
[1] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[3] Univ Naples Federico II, Dept Med & Surg, Naples, Italy
[4] Univ Salerno, Dept Med & Surg, I-84100 Salerno, Italy
关键词
B-cell lymphoma 6 (BCL6); CD10; cell block; diffuse large B-cell lymphoma (DLBCL); fine-needle aspiration (FNA); non-Hodgkin lymphoma; multiple myeloma oncogene 1 (MUM1); FINE-NEEDLE-ASPIRATION; MOLECULAR SUBTYPES; CYTOLOGY; SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOCYTOCHEMISTRY; CLASSIFICATION; CHEMOTHERAPY; SUBSET;
D O I
10.1002/cncy.21626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDGene expression profiling has divided diffuse large B-cell lymphoma (DLBCL) into 2 main subgroups: germinal center B (GCB) and non-GCB type. This classification is reproducible by immunohistochemistry using specific antibodies such as CD10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1 (MUM1). Fine-needle aspiration (FNA) plays an important role in the diagnosis of non-Hodgkin lymphoma, and in some cases FNA may be the only available pathological specimen. The objectives of the current study were to evaluate CD10, BCL6, and MUM1 immunostaining on FNA samples by testing the CD10, BCL6, and MUM1 algorithm on both FNA cell blocks (CB) and conventional smears (CS), evaluating differences in CB and CS immunocytochemical (ICC) performance, and comparing results with histological data. METHODSThirty-eight consecutive DLBCL cases diagnosed by FNA were studied. Additional passes were used to prepare CB in 22 cases and CS in 16 cases; the corresponding sections and smears were immunostained using CD10, BCL6, and MUM1 in all cases. The data obtained were compared with histological immunostaining in 24 cases. RESULTSICC was successful in 33 cases (18 CB and 15 CS) and not evaluable in 5 cases (4 CB and 1 CS). The CD10-BCL6-MUM1 algorithm subclassified DLBCL as GCB (9 cases) and non-GCB (24 cases). ICC data were confirmed on histologic staining in 24 cases. CONCLUSIONSCD10, BCL6, and MUM1 ICC staining can be performed on FNA samples. The results herein prove it is reliable both on CB and CS, and is equally effective and comparable to immunohistochemistry data. (c) 2015 American Cancer Society.
引用
收藏
页码:135 / 143
页数:9
相关论文
共 27 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]   Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome [J].
Barrans, SL ;
Fenton, JAL ;
Banham, A ;
Owen, RG ;
Jack, AS .
BLOOD, 2004, 104 (09) :2933-2935
[3]   Establishing a protocol for immunocytochemical staining and chromogenic in situ hybridization of Giemsa and Diff-Quick prestained cytological smears [J].
Beraki, Elsa ;
Olsen, Thale Kristin ;
Sauer, Torill .
CYTOJOURNAL, 2012, 9
[4]  
Bertram HC, 2001, AM J CLIN PATHOL, V116, P191
[5]   A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy [J].
Choi, William W. L. ;
Weisenburger, Dennis D. ;
Greiner, Timothy C. ;
Piris, Miguel A. ;
Banham, Alison H. ;
Delabie, Jan ;
Braziel, Rita M. ;
Geng, Huimin ;
Iqbal, Javeed ;
Lenz, Georg ;
Vose, Julie M. ;
Hans, Christine P. ;
Fu, Kai ;
Smith, Lynette M. ;
Li, Min ;
Liu, Zhongfeng ;
Gascoyne, Randy D. ;
Rosenwald, Andreas ;
Ott, German ;
Rimsza, Lisa M. ;
Campo, Elias ;
Jaffe, Elaine S. ;
Jaye, David L. ;
Staudt, Louis M. ;
Chan, Wing C. .
CLINICAL CANCER RESEARCH, 2009, 15 (17) :5494-5502
[6]   Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium [J].
de Jong, Daphne ;
Rosenwald, Andreas ;
Chhanabhai, Mukesh ;
Gaulard, Philippe ;
Klapper, Wolfram ;
Lee, Abigail ;
Sander, Birgitta ;
Thorns, Christoph ;
Campo, Elias ;
Molina, Thierry ;
Norton, Andrew ;
Hagenbeek, Anton ;
Horning, Sandra ;
Lister, Andrew ;
Raemaekers, John ;
Gascoyne, Randy D. ;
Salles, Gilles ;
Weller, Edie .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :805-812
[7]   Improving Outcomes for Patients with Diffuse Large B-Cell Lymphoma [J].
Flowers, Christopher R. ;
Sinha, Rajni ;
Vose, Julie M. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2010, 60 (06) :393-408
[8]  
Fowler LJ, 2008, ARCH PATHOL LAB MED, V132, P373, DOI 10.1043/1543-2165(2008)132[373:AOITC]2.0.CO
[9]  
2
[10]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282